PFM Health Sciences’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.4M | Buy |
254,510
+7,675
| +3% | +$633K | 1.86% | 15 |
|
|
2025
Q4 | $21M | Sell |
246,835
-134,489
| -35% | -$11M | 2.1% | 13 |
|
|
2025
Q3 | $29.7M | Sell |
381,324
-11,179
| -3% | -$873K | 2.28% | 9 |
|
|
2025
Q2 | $30.7M | Buy |
392,503
+12,549
| +3% | +$936K | 2.61% | 12 |
|
|
2025
Q1 | $27.5M | Sell |
379,954
-214,218
| -36% | -$15.3M | 2% | 16 |
|
|
2024
Q4 | $44M | Buy |
594,172
+203,309
| +52% | +$14.2M | 2.73% | 9 |
|
|
2024
Q3 | $25.8M | Sell |
390,863
-349,397
| -47% | -$25.4M | 1.46% | 24 |
|
|
2024
Q2 | $68.4M | Hold |
740,260
| – | – | 3.38% | 8 |
|
|
2024
Q1 | $70.7M | Hold |
740,260
| – | – | 3.33% | 5 |
|
|
2023
Q4 | $56.4M | Buy |
740,260
+37,672
| +5% | +$2.62M | 3.39% | 7 |
|
|
2023
Q3 | $48.7M | Hold |
702,588
| – | – | 2.29% | 13 |
|
|
2023
Q2 | $66.3M | Buy |
702,588
+53,955
| +8% | +$4.69M | 2.57% | 9 |
|
|
2023
Q1 | $53.7M | Buy |
648,633
+118,603
| +22% | +$9.32M | 2.37% | 10 |
|
|
2022
Q4 | $39.5M | Buy |
530,030
+49,774
| +10% | +$3.84M | 1.42% | 30 |
|
|
2022
Q3 | $39.7M | Buy |
480,256
+142,101
| +42% | +$13.7M | 1.44% | 31 |
|
|
2022
Q2 | $32.2M | Hold |
338,155
| – | – | 1.23% | 39 |
|
|
2022
Q1 | $39.8M | Sell |
338,155
-35,337
| -9% | -$3.96M | 1.49% | 30 |
|
|
2021
Q4 | $48.4M | Sell |
373,492
-139,513
| -27% | -$16.3M | 1.65% | 25 |
|
|
2021
Q3 | $58.1M | Hold |
513,005
| – | – | 1.71% | 22 |
|
|
2021
Q2 | $53.1M | Hold |
513,005
| – | – | 1.67% | 20 |
|
|
2021
Q1 | $42.9M | Buy |
513,005
+25,163
| +5% | +$2.13M | 1.31% | 25 |
|
|
2020
Q4 | $44.5M | Hold |
487,842
| – | – | 1.57% | 23 |
|
|
2020
Q3 | $38.9M | Buy |
487,842
+94,407
| +24% | +$7.37M | 1.8% | 19 |
|
|
2020
Q2 | $27.2M | Buy |
393,435
+38,259
| +11% | +$2.72M | 1.41% | 28 |
|
|
2020
Q1 | $22.3M | Buy |
355,176
+45,339
| +15% | +$3.27M | 1.83% | 23 |
|
|
2019
Q4 | $24.1M | Sell |
309,837
-445,425
| -59% | -$34.8M | 1.15% | 34 |
|
|
2019
Q3 | $55.4M | Sell |
755,262
-613,815
| -45% | -$43.1M | 1.63% | 22 |
|
|
2019
Q2 | $84.3M | Buy |
1,369,077
+288,156
| +27% | +$17.4M | 1.6% | 20 |
|
|
2019
Q1 | $68.9M | Sell |
1,080,921
-541,560
| -33% | -$30.9M | 1.52% | 26 |
|
|
2018
Q4 | $82.8M | Buy |
1,622,481
+54,465
| +3% | +$2.76M | 2.2% | 10 |
|
|
2018
Q3 | $91M | Buy |
1,568,016
+58,281
| +4% | +$2.85M | 1.33% | 23 |
|
|
2018
Q2 | $73.3M | Sell |
1,509,735
-170,250
| -10% | -$7.95M | 1.15% | 30 |
|
|
2018
Q1 | $78.1M | Sell |
1,679,985
-999,864
| -37% | -$43.4M | 1.59% | 23 |
|
|
2017
Q4 | $101M | Sell |
2,679,849
-432,423
| -14% | -$15.9M | 2.39% | 5 |
|
|
2017
Q3 | $113M | Buy |
3,112,272
+1,267,839
| +69% | +$48.4M | 2.23% | 9 |
|
|
2017
Q2 | $72.7M | Buy |
1,844,433
+474,135
| +35% | +$17.3M | 1.96% | 16 |
|
|
2017
Q1 | $43M | Sell |
1,370,298
-1,211,871
| -47% | -$37.9M | 1.08% | 36 |
|
|
2016
Q4 | $80.7M | Sell |
2,582,169
-121,620
| -4% | -$3.94M | 2.27% | 12 |
|
|
2016
Q3 | $109M | Sell |
2,703,789
-601,314
| -18% | -$22.6M | 3.18% | 4 |
|
|
2016
Q2 | $110M | Buy |
3,305,103
+398,082
| +14% | +$13.6M | 3.32% | 4 |
|
|
2016
Q1 | $85.5M | Sell |
2,907,021
-615,273
| -17% | -$17M | 2.64% | 11 |
|
|
2015
Q4 | $92.7M | Sell |
3,522,294
-1,202,286
| -25% | -$31.2M | 2.82% | 10 |
|
|
2015
Q3 | $112M | Sell |
4,724,580
-638,358
| -12% | -$15.4M | 3.15% | 8 |
|
|
2015
Q2 | $127M | Buy |
5,362,938
+1,739,712
| +48% | +$39.3M | 3.22% | 7 |
|
|
2015
Q1 | $86M | Sell |
3,623,226
-339,726
| -9% | -$7.62M | 2.37% | 11 |
|
|
2014
Q4 | $84.1M | Buy |
+3,962,952
| New | +$79.6M | 1.96% | 16 |
|
Other funds holding EW
VCM
VPM
PFM Health Sciences's EW Position: Q1 2026 in Review
PFM Health Sciences increased its Edwards Lifesciences (EW) stake by 3.1% in Q1 2026, buying an estimated $633K and bringing the position to 254,510 shares worth $20.4M. The position accounts for 1.86% of the portfolio, ranked #15.
PFM Health Sciences first reported a position in EW in Q4 2014 and has held it in 46 quarters since. The position peaked at $127M in Q2 2015. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- PFM Health Sciences held 254,510 shares of Edwards Lifesciences worth $20.4M as of Q1 2026.
- PFM Health Sciences bought 7,675 Edwards Lifesciences shares in Q1 2026, an estimated $633K.
- Edwards Lifesciences made up 1.86% of PFM Health Sciences's portfolio in Q1 2026, its #15 holding.
- PFM Health Sciences first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 46 quarters since.
- PFM Health Sciences's Edwards Lifesciences position peaked at $127M in Q2 2015.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.